Innovative Diagnostics to Help Manage HSCT Challenges Post-Transplant 2022

Innovative Diagnostics to Help Manage HSCT Challenges Post-Transplant  is Available On-Demand.

Originally presented at the Tandem Meetings | Transplantation and Cellular Therapy Meetings of CIBMTR and ASBMT, we’ve segmented by topic so you can view each these great presentations in 30 minutes.

This promotional activity is provided by Eurofins Transplant Diagnostics and is not certified for continuing education credit. The content of this Product & Innovation Theater and opinions expressed by presenters are those of the sponsor or presenters and not of the Tandem Meetings, ASTCT or CIBMTR

How Serum Biomarkers can Guide aGVHD Therapy

Results not matching up with GVHD, TMA (Thrombotic Microangiopathy) and COD.

Learn about the biology of aGVHD, and view case studies showcasing how aGVHD Algorithm Testing: Pre-Symptomatic, Symptomatic Onset, and Post-Treatment can aid in decision making for aGVHD patients.

  • Learn how the MAGIC Algorithm is used as a “liquid biopsy”
  • Benefit of serial monitoring GVHD values when determining levels of risk, using the Ann Arbor scale.
  • Earlier detection of GVHD is critical, as more lower risk recipients are developing GVHD
  • Utilization of MAGIC Algorithm and MAP to aid in immunosuppression therapy decisions.
  • Use of MAP information as a predictor of GI involvement in the absence of clinical symptoms.

Presented by:
Dr. James Ferrara, MD, DSc
Mount Sinai Medical Center

The use of Cytomegalovirus (CMV) T Cell Immunity Panel to Assess the Risk of Clinically Significant CMV Infection in Recipients of Cellular Therapy with Low Level CMV Viremia

Learn about an ongoing study which Dr. Chemaly and his team at MD Anderson have utilized CMV inSIGHT™ T Cell Immunity testing to:

  • Identify cellular therapy recipients (both on and off letermovir for prophylaxis) who are high risk for clinically significant CMV infection.
  • Assess the benefit of early treatment of low level CMV viremia who are not on letermovir prophylaxis and high risk for clinically significant CMV infection
  • Determine utility of the CMV inSIGHT™ T Cell Immunity test in the management of low level CMV viremia in high and low risk patient populations on letermovir.

Presented by: 
Dr. Roy Chemaly, MD, MPH, FIDSA, FACP
MD Anderson Cancer Center

Q&A by:
Dr. Fareed Khawaja, MD
MD Anderson Cancer Center